Table 2. Rates of high-risk prescribing at baseline, and 6 and 12 months post-intervention for study population and for practice population overall
Study populationaPractice populationb
Outcome measureBaseline6-month
n/N (%)
P-value12-month
n/N (%)
P-valuec 6-month
n/N (%)
12-month
n/N (%)
Primary outcome: high-risk prescribing70/870 (8.0)47/807 (5.8);
52/870 (6.0) LVCF
0.030.0462/757 (8.2);
74/870 (8.5) LVCF
0.90.771/890 (8.0)101/1026 (9.8)
Secondary outcomes
High-risk prescribing among patients
with any gastrointestinal risk factor
35/649 (5.4)26/596 (4.4);
29/649 (4.5) LVCF
0.40.433/554 (6.0);
42/649 (6.5) LVCF
0.60.439/698 (5.6)52/731 (7.1)
High-risk prescribing amongst patients
with any renal risk factor
41/476d (8.6)22/444 (5.0);
25/476 (5.3) LVCF
0.0070.00833/414 (8.0);
38/476 (8.0) LVCF
0.70.738/365 (10.4)61/536 (11.4)
High-risk prescribing among patients
with congestive heart failure
1/27 (3.7)1/23 (4.4);
1/27 (3.7) LVCF
0.91.01/21 (4.8);
1/27 (3.7) LVCF
0.91.01/26 (3.9)1/25 (4.0)
  • aPatients vulnerable at baseline; that is at increased risk of adverse drug events (ADE) when prescribed NSAID and/or antiplatelet medicines (see Table 1). bAll practice vulnerable patients; that is includes patients who were not vulnerable at baseline but who have become so at 6 months and/or 12 months. cCompared with baseline.d32/870 (3.7%) patients were included as at-risk of ADE due to a low eGFR, where it could not be confirmed that the latest eGFR was still <60. LVCF = last value carried forward, which assumes that those lost to follow-up (left the practice or died) had the same high-risk prescribing status as baseline.